More than 8 million people in Europe and the US suffer from moderate to severe mitral valve regurgitation (blood leaking back into the heart´s left atrium). If left untreated, this condition may ultimately lead to heart failure. Open-heart surgery is the current gold-standard for treating mitral valve prolapse. Due to significant procedure risks for the patients, up to 50% of the affected population are left untreated. The Mitral Butterfly implant is based on a unique physiological design that can be deployed in one-step. Transcatheter implantation provides for a minimally invasive procedure.